The presence of KRAS mutations was a significant prognostic factor for better OS in NSCLC patients treated with checkpoint inhibitors (HR = 0.89, 95% CI: 0.79–0.99) (Figure 2). Here, KRAS is linked to non-small cell lung carcinoma.